Amylyx’s ALS Drug Brings Questions On Efficacy Data Robustness To US FDA Panel

 
• By Sue Sutter
Line graph
Amylyx relied on a 'questionable linearity assumption' in its primary endpoint analysis for the CENTAUR study, FDA said. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers